MaaT Pharma, leader in the development of drugs based on intestinal microbiota in oncology, receives funding from the State for the clinical development of MaaT033 as part of the France 2030 Plan
• MaaT Pharma secures significant funding in accordance with one of the objectives of the Health Innovation 2030 plan, the health component of “France 2030”, led by the Health Innovation Agency, dedicated to accelerating the national strategy for the production of biotherapies and innovative therapies with a target of at least 20 biomedicines produced in France.
• MaaT Pharma is set to receive €7.4 million from the State over two years, with upfront payments extending the financial stability of the Company until the end of the second quarter of 2024, subject to achievement of project milestones. This will result in a net cash increase of €3.1 million during the first half of 2024, following a restructuring of previous financing linked to the immuno-oncology (METIO) program.
• The financing was announced today during a video produced by the Minister of Industry, on the occasion of the official inauguration of the production plant built for MaaT Pharma in partnership with Skyepharma.